SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
| Price | $4.49 |
|---|---|
| Market cap | $28.24M |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Exchange | NASDAQ |
| 52-week range | 3.53-9.2 |
| Beta | 1.11 |
Explore SCYX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.